UK HealthTech Companies Return to ABHI US Accelerator for 2026
Topic : International, News and Press Type : Press Release
Following a landmark year in 2025, eight UK HealthTech innovators have renewed their commitment to the ABHI US Accelerator for 2026 as they look to further penetrate the $5 trillion US healthcare market.
The 2025 programme supported 25 UK HealthTech companies target this market through a comprehensive schedule of US-focused activities. Those returning for 2026, in order to build on the progress made, include Haigh Engineering, VitVio, Adaptix, Megi Health, Open Medical, Psyomics Ltd, Aide Health and Newton’s Tree.
Paul Benton, Managing Director of International at ABHI, said: “For almost a decade, the US Accelerator has supported many brilliant UK HealthTech innovators enter the US healthcare market.
“We are thrilled to welcome back last year's alumni into our 2026 cohort as the US continues to seek the world-class digital health innovation that is the hallmark of the UK tech sector.”
The 2025 Accelerator delivered:
- Four US trade missions.
- Engagement with 40+ health systems and hospitals.
- Meetings with 125+ senior healthcare leaders.
- Connections with healthcare stakeholder groups in six states and 11 major cities.
Companies also received practical insight into how to navigate US reimbursement, regulation, fundraising, and sales strategy, including expert input from c-suite-level leaders from the likes of Baptist Health and the Cleveland Clinic. The recent End of Year Report provides further details of the year’s dynamic programme.
Femtech health innovator Megi Health is continuing its US market mission following strategic and commercial support from ABHI.
Its founder Ines Knežević said: “ABHI truly de-risked our US entry strategy and accelerated our sales pipeline within just a few months. We’re excited for next year and all the adventures ahead.”
Chris Rogers, the global commercial director of Adaptix, was equally supportive of the programme. He said: “Attending the 2025 US Accelerator programme has allowed Adaptix Ltd the opportunity to engage and connect with C-suite decision makers in health systems across the USA.
“This has been incredibly important as we moved towards our FDA 510k. Insights and feedback gathered has been invaluable to validate and support our commercial plans. With our Ortho350 now FDA cleared, we are looking forward to the 2026 missions and participating in the programme next year.”
The ABHI US Accelerator Programme 2026 will offer trade missions to Tennessee, Texas and destinations along the east coast. This year will include deeper senior-level engagement and tailored market insight for UK HealthTech companies looking to grow in the US.
Companies interested in taking part in the ABHI US Accelerator Programme 2026 are encouraged to get in touch at: USAccelerator@abhi.org.uk to find out more.